Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Rectify is developing Positive Functional Modulators (PFMs), disease-modifying precision therapeutics that restore ABC transporter function for patients with serious genetic diseases.

ABC transporters are a 48-member family of membrane-bound proteins with etiologic loss-of-function mutations in multiple organ systems and therapeutic areas including the lungs, liver, gastrointestinal tract, eye, and central nervous system.

Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Next generation ocular gene
therapies for vision restoration
and vision preservation

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Patient-directed oncology therapies
across immune and cancer cell pathways
IPO Mar 2021 (NASDAQ: IKNA)

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Novel therapeutics
targeting
diseases of aging

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Precision therapeutics for
genetically-defined dry AMD
(NASDAQ: GMTX) Jan 2021

Advancing novel therapies for people
with rare cardiopulmonary disease
– IPO Jun 2021 (NASDAQ: AVTE)

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Rapidly developing new cancer
treatments for people of all ages
– IPO Jun 2021 (NASDAQ: DAWN)

Harnessing the power of microglia to
transform treatments for neuro-
degenerative diseases (NASDAQ: VIGL)

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

Cell and gene therapies
for rare diseases
IPO Jun 2018 (NASDAQ: AVRO)

Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

First-in-class RNA therapies
for severe genetic diseases
IPO Jun 2018 (NASDAQ: TBIO)

Designing Synthetic Biotic
living medicines to treat disease
(NASDAQ: SYBX)

Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics

Bispecific antibodies
to improve the treatment
of serious diseases

Breakthrough computer-aided
drug design
for transformative medicines

Leading the
next frontier in
RNA therapeutics

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Novel therapeutics
for severe
respiratory diseases

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Precision therapeutics
for genetically defined
diseases

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Building
the future of
gene therapy

Broadening the reach and
impact of precision medicine
to more people with cancer

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Preventing axonal degeneration in
patients with neurological diseases
Sold to Lilly (NYSE: LLY) Oct 2020

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Targeting progranulin and
lysosomal biology to treat
neurodegenerative diseases

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Developing treatments for
complex rare diseases
(NASDAQ: LRMR)

Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Pioneering targeted therapies
for serious muscle diseases –
IPO Sep 2020 (NASDAQ: DYN)

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

Breakthrough therapies for neuro-
logical & psychiatric conditions
– Sold to Novartis Dec 2020

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Harnessing the immune system to
defeat cancer with tumor-selective
immunotherapies (NASDAQ: XLO)

Curie Therapeutics is discovering and developing safe, effective, and highly targeted radiopharmaceuticals.

Scalable, re-dosable, non-viral
gene therapy for genetic diseases
IPO Jun 2020 (NASDAQ: GBIO)

Harnessing the power of the epigenome to develop precision genomic therapeutics.

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Developing first-in-class
medicines for medical conditions
prevalent in older adults

Targeting regulators of
innate and adaptive immunity
to restore immune homeostasis

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Reprogramming RNA processing
to address underlying
drivers of disease

New class of
regulated cell and
gene therapies

Applying new insights in
hepcidin biology to
treat hematologic diseases

Discovering new medicines
for severe
neurodegenerative diseases

Engineered
B cells
as medicines

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007